Sustainability is the word for this company 1. $901 million net loss
2. No marketable product
3. At losing end compared with Moderna, Pfizer and others
So, if the FDA within the next month or so approves it vaccine trial, it might boost the share price temporarily but in the long term, it has to have a better strategy to compete with the bigger boys.
That means, if I wanna long, it will be more of a speculative trade than investment for the long term.